

AstraZeneca Docket No. 100829-1P US

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of: **Peter Bernstein et al.**
International Application Number: **PCT/SE2003/001399**
International Filing Date: **September 8, 2003**
For: **NAPHTHYL ETHER COMPOUNDS AND THEIR USE**
Group Art Unit: **Not yet allocated**
Examiner: **Not yet allocated**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications which they believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

The references listed on the attached Form PTO/SB/08a and PTO/SB/08b were cited by the Examiner in the International Search Report.

This Information Disclosure Statement is being filed within three months of the filing of the application. Accordingly, no fee is required for consideration of the references filed herewith.

Respectfully submitted,

Dated: March 8, 2005

By: 

Kenneth F. Mitchell, Ph.D.
Attorney for Applicants
Reg. No. 42,007
Telephone: 302/886-7466

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known 10/527280	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	IA NO. PCT/SE2003/001399
				Filing Date	Intl. Filing Ssept. 8, 2003
				First Named Inventor	Peter BERNSTEIN
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	100829-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GRAEME I. STEVENSON ET AL, "4,4-Disubstituted Piperidines: A New Class of NK1 Antagonist," J. Med. Chem., Vol. 38 (No. 8), p. 1264-1266, (1995).	
		GRAEME I. STEVENSON ET AL, "4,4 Disubstituted Piperidine High-Affinity NK1, Antagonists: Structure-Activity Relationships and in Vivo Activity," J. Med. Chem., Vol. 41 (No. 23), p. 4623-4635, (November 23, 1998).	
		JASON M. ELLIOTT ET AL, "4,4-Disubstituted Cyclohexylamine NK1 Receptor Antagonists I," Bioorganic & Medicinal Chemistry Letters, Vol. 12 (No. 13), p. 1755-1758, table 3, compound nos. 23, 27 (July 8, 2002).	
		THOMAS RYCKMANS ET AL, "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants," Bioorganic & Medicinal Chemistry Letters, Vol. 12 (No. 2), p. 261-264, (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.